X4 Pharmaceuticals Appoints E. Lynne Kelley, M.D. as Chief Medical Officer

CAMBRIDGE, Mass.–(BUSINESS WIRE)–X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage
biopharmaceutical company focused on the development of novel
therapeutics for the treatment of rare diseases, today announced the
appointment of E. Lynne Kelley, M.D., FACS, as the company’s Chief
Medical Officer (CMO). Dr. Kelley brings more than a decade of
experience driving clinical development and global expansion of novel
pharmaceutical products at both emerging and established life sciences
companies. Dr. Kelley is a Board Certified General and Vascular Surgeon.

“We are thrilled to have Lynne join our team as Chief Medical Officer,”
said Paula Ragan, Ph.D., President and Chief Executive Officer of X4
Pharmaceuticals. “Her broad medical and biopharmaceutical industry
experience, along with her deep understanding of complex regulatory
applications, will be invaluable as we execute our global Phase 3
pivotal trial in WHIM syndrome, a rare genetic, primary immunodeficiency
disease, and advance our pipeline across additional rare and ultra-rare

“This is an incredibly exciting time for X4 with its many recent
accomplishments and ongoing clinical development efforts. I look forward
to working with this very talented and dedicated team of industry
experts to deliver on a shared goal of bringing novel therapies to
patients with rare disease who have limited treatment options,”
commented Dr. Kelley.

Before joining X4, Dr. Kelley was CMO of Massachusetts-based
biopharmaceutical company Histogenics Corporation (Nasdaq: HSGX), where
she led the development of restorative cell therapies to replace damaged
cartilage and oversaw the completion of a Phase 3 clinical trial and
regulatory submission for the company’s lead program. Dr. Kelley
previously served as CMO of Senseonics Holdings, Inc. (Nasdaq: SENS) and
held leadership positions in clinical development roles at global
companies such as Becton, Dickinson and Company, Kimberly-Clark
Corporation, and Boston Scientific Corporation.

Dr. Kelley received her medical degree from Dartmouth Medical School and
her bachelor’s degree in biology from Boston University. Dr. Kelley is a
fellow of the American College of Surgeons and has authored numerous
articles for peer-reviewed publications. She trained at Dartmouth
Hitchcock Hospital and Massachusetts General Hospital, and was a
practicing surgeon at Yale University. Dr. Kelley was named Fellow of
the American College of Surgeons and was awarded an NIH research grant
at Harvard and the Marco Polo Fellowship studying at Hospital Henri
Mondor of the University Paris Hospital System.

About X4 Pharmaceuticals

X4 Pharmaceuticals is developing novel therapeutics designed to improve
immune cell trafficking to treat rare diseases, including primary
immunodeficiencies and certain cancers. X4’s oral small molecule drug
candidates antagonize the CXCR4 pathway, which plays a central role in
immune surveillance. X4’s most advanced product candidate, mavorixafor
(X4P-001), is expected to commence a global Phase 3 pivotal trial in
patients with WHIM syndrome, a rare genetic, primary immunodeficiency
disease, in the second quarter of 2019 and is currently also under
investigation in a Phase 2a clinical trial in clear cell renal cell
carcinoma. X4 was founded and is led by a team with extensive product
development and commercialization expertise, including several former
members of the Genzyme leadership team, and is located in Cambridge,

Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, as
amended. The words “may,” “will,” “could,” “would,” “should,” “expect,”
“plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “target” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
Forward-looking statements include statements regarding plans for, or
progress, scope, cost, duration or results or timing for the initiation,
completion or availability of results of development of mavorixafor
(X4P-001) or any of our other product candidates or programs, including
regarding the Phase 3 clinical trial of mavorixafor for the treatment of
patients with WHIM syndrome, the target indication(s) for development,
the size, design, population, location, conduct, objective, duration or
endpoints of any clinical trial, or the timing for initiation or
completion of or reporting of results from any clinical trial, the
potential benefits of mavorixafor, or any other product candidate or
program or the commercial opportunity in any target indication. These
statements are subject to various risks and uncertainties, actual
results could differ materially from those projected and X4 cautions
investors not to place undue reliance on the forward-looking statements
in this press release. These risks and uncertainties include, without
limitation, the risk that trials and studies may be delayed and may not
have satisfactory outcomes, potential adverse effects arising from the
testing or use of mavorixafor or other product candidates, and the risk
that costs required to develop mavorixafor or other product candidates
or to expand our operations will be higher than anticipated. Any
forward-looking statements in this press release are based on
management’s current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed or
implied by any forward-looking statements contained in this press
release, including, without limitation, the risks and uncertainties
described in the section entitled “Risk Factors” in X4’s most recent
Annual Report on Form 10-K filed with the Securities and Exchange
Commission (SEC), as updated by X4’s Current Report on Form 8-K filed
with the SEC on April 11, 2019, and in other filings X4 makes with the
SEC from time to time. X4 undertakes no obligation to update the
information contained in this press release to reflect subsequently
occurring events or circumstances.


Stephanie Carrington
Westwicke, an ICR
[email protected]

Darcie Robinson
Westwicke, an ICR company
[email protected]

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.